GTC
CLDX icon

Ghost Tree Capital’s Celldex Therapeutics CLDX Stock Holding History

Ghost Tree Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-400,000
Closed -$10.8M – 47
2022
Q2 		$10.8M Buy
+400,000
New +$11.6M 5.62% 2

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Ghost Tree Capital's CLDX Position: Q2 2022 in Review

Ghost Tree Capital sold out of Celldex Therapeutics (CLDX) in Q2 2022, closing a stake of 300,000 shares — an estimated $8.71M sold.

Ghost Tree Capital first reported a position in CLDX in Q1 2021 and held it in 5 quarters. The position peaked at $13.8M in Q3 2021. 157 funds tracked by Wall St. Rank hold CLDX as of Q2 2022.

  • Ghost Tree Capital reported no remaining Celldex Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ghost Tree Capital sold 300,000 Celldex Therapeutics shares in Q2 2022, an estimated $8.71M.
  • Ghost Tree Capital first reported a position in Celldex Therapeutics in Q1 2021 and held it in 5 quarters.
  • Ghost Tree Capital's Celldex Therapeutics position peaked at $13.8M in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2022.

Based on Ghost Tree Capital's 13F filing for Q2 2022, filed 15 Aug 2022.